Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.74 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | CTSB | P07858 | 2/20 | 0.67 |
| ▸ | CTSS | P25774 | 2/20 | 0.67 |
| ▸ | CTSK | P43235 | 2/20 | 0.67 |
| ▸ | ACE | P12821 | 5/20 | 0.66 |
| ▸ | HPGDS | O60760 | 2/20 | 0.64 |
| ▸ | MME | P08473 | 3/20 | 0.62 |
| ▸ | CPA1 | P15085 | 3/20 | 0.62 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.60 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8196220 | 1.00 | PTPN1 (0.74) | PTPN1CA2CA1L3MBTL1CTSB | |
| SCHEMBL10033681 | 0.94 | PTPN1 (0.69) | PTPN1CA2CA1L3MBTL1CTSB | |
| SCHEMBL6857183 | 0.94 | PTPN1 (0.69) | PTPN1CA2CA1L3MBTL1CTSB | |
| SCHEMBL111236 | 0.92 | ACE (0.76) | PTPN1CA2CA1L3MBTL1CTSS | |
| SCHEMBL111235 | 0.92 | ACE (0.76) | PTPN1CA2CA1L3MBTL1CTSS | |
| SCHEMBL528464 | 0.92 | ACE (0.76) | PTPN1CA2CA1L3MBTL1CTSS | |
| SCHEMBL6513134 | 0.91 | CA2 (0.68) | PTPN1CA2CA1L3MBTL1CTSB | |
| Hydrochloric Acid SCHEMBL10622640 | 0.90 | ACE (0.74) | PTPN1CA2CA1L3MBTL1CTSS | |
| SCHEMBL28419447 | 0.90 | ACE (0.74) | PTPN1CA2CA1L3MBTL1CTSS | |
| SCHEMBL28419446 | 0.90 | ACE (0.74) | PTPN1CA2CA1L3MBTL1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263826-A2 | MEANS AND METHODS FOR DETOXIFYING OCHRATOXIN A | DSM Austria GmbH (AT) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022129517-A2 | MEANS AND METHODS FOR DETOXIFYING OCHRATOXIN A | ERBER AKTIENGESELLSCHAFT (AT) | 2022-06-23 | — | — | WO | disclosed |
| CN-114645037-A | Means and methods for detoxification of ochratoxin A | 艾尔柏股份公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2030981-A1 | Compounds for proteasome enzyme inhibition | Proteolix, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2005111008-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | PTPN1 871/4885CA2 4151/4885CA1 2202/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | PTPN1 678/4885CA2 3451/4885CA1 1866/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | PTPN1 678/4885CA2 3451/4885CA1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.